<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01043146</url>
  </required_header>
  <id_info>
    <org_study_id>COR-1-01</org_study_id>
    <secondary_id>EudraCT2008-007745-31</secondary_id>
    <nct_id>NCT01043146</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide</brief_title>
  <acronym>COR-1-01</acronym>
  <official_title>A Single-Blind Placebo-Controlled Dose Escalating Safety and Pharmacokinetic Study of an Acute Intravenous Administration of Cor-1, An Anti-ß1 Receptor Antibody Cyclopeptide, in Five Different Strengths in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corimmun GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corimmun GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Trial objectives:

      To evaluate the pharmacokinetics and -dynamics of five strengths of COR-1 (10, 40, 80, 160,
      240 mg) in 50 healthy, male volunteers after single intravenous administration (8 subjects on
      verum per dose level, 10 subjects receiving placebo)

      Secondary objectives:

      To evaluate safety and tolerability by using adverse events (AEs) and vital signs
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Trial objective:

      To evaluate the pharmacokinetics and -dynamics of five strengths of COR-1 (10, 40, 80, 160,
      240 mg) in healthy, male volunteers after single intravenous administration

      Secondary objectives:

      To evaluate safety and tolerability by using adverse events (AEs), vital signs including
      blood pressure/pulse rate (BP/PR), electrocardiographic examinations (12 lead ECG),
      evaluation of antibody titer and safety laboratory tests (biochemistry, hematology,
      coagulation, urinalysis)

      Methodology:

      Mono-center, single-blind, dose escalating study with five dose levels (8 subjects on verum
      per dose level, 2 subjects receiving placebo) in a total of 50 volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants Reporting Adverse Events (AEs)</measure>
    <time_frame>45 days</time_frame>
    <description>To assess the safety and tolerability of COR-1.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>COR-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intravenous 0.9 % NaCl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COR-1</intervention_name>
    <description>single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1</description>
    <arm_group_label>COR-1</arm_group_label>
    <other_name>cyclic peptide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>intravenous 0.9 % NaCl</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, male Caucasians between 18 and 45 years of age, inclusive

          -  Normotensive subjects (systolic BP &lt;140 mmHg and diastolic BP &lt;90 mmHg)

          -  Body mass index (BMI) 19-27, minimal weight 60 kg

          -  Negative results in HIV antibody, HBs antigen (HBsAg) and HCV tests, and negative
             result in anti-ß1-receptor-autoantibody screening

          -  Signed Informed Consent Form

          -  Normal or clinically irrelevant laboratory findings

        Exclusion Criteria:

          -  Autoimmune disorders

          -  Kidney diseases

          -  Liver diseases, liver function impairments
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariola Lappo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ABX CRO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ABX-CRO</name>
      <address>
        <city>Goerlitz</city>
        <state>Saxonia</state>
        <zip>02826</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2010</study_first_submitted>
  <study_first_submitted_qc>January 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2010</study_first_posted>
  <results_first_submitted>October 26, 2012</results_first_submitted>
  <results_first_submitted_qc>March 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 8, 2013</results_first_posted>
  <last_update_submitted>March 5, 2013</last_update_submitted>
  <last_update_submitted_qc>March 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti-beta1 adrenergic receptor</keyword>
  <keyword>autoantibody</keyword>
  <keyword>cyclic peptide</keyword>
  <keyword>heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>intravenous 0.9 % NaCl</description>
        </group>
        <group group_id="P2">
          <title>10 mg COR-1</title>
          <description>single intravenous administration</description>
        </group>
        <group group_id="P3">
          <title>40 mg COR-1</title>
          <description>single intravenous administration</description>
        </group>
        <group group_id="P4">
          <title>80 mg COR-1</title>
          <description>single intravenous administration</description>
        </group>
        <group group_id="P5">
          <title>160 mg COR-1</title>
          <description>single intravenous administration</description>
        </group>
        <group group_id="P6">
          <title>240 mg COR-1</title>
          <description>single intravenous administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>intravenous 0.9 % NaCl</description>
        </group>
        <group group_id="B2">
          <title>10 mg COR-1</title>
          <description>single intravenous administration</description>
        </group>
        <group group_id="B3">
          <title>40 mg COR-1</title>
          <description>single intravenous administration</description>
        </group>
        <group group_id="B4">
          <title>80 mg COR-1</title>
          <description>single intravenous administration</description>
        </group>
        <group group_id="B5">
          <title>160 mg COR-1</title>
          <description>single intravenous administration</description>
        </group>
        <group group_id="B6">
          <title>240 mg COR-1</title>
          <description>single intravenous administration</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="8"/>
            <count group_id="B7" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.1" spread="8.61"/>
                    <measurement group_id="B2" value="32.5" spread="7.09"/>
                    <measurement group_id="B3" value="33.1" spread="8.94"/>
                    <measurement group_id="B4" value="31.9" spread="7.77"/>
                    <measurement group_id="B5" value="30.1" spread="8.66"/>
                    <measurement group_id="B6" value="27.5" spread="8.35"/>
                    <measurement group_id="B7" value="31.6" spread="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants Reporting Adverse Events (AEs)</title>
        <description>To assess the safety and tolerability of COR-1.</description>
        <time_frame>45 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>intravenous 0.9 % NaCl</description>
          </group>
          <group group_id="O2">
            <title>10 mg COR-1</title>
            <description>single intravenous administration</description>
          </group>
          <group group_id="O3">
            <title>40 mg COR-1</title>
            <description>single intravenous administration</description>
          </group>
          <group group_id="O4">
            <title>80 mg COR-1</title>
            <description>single intravenous administration</description>
          </group>
          <group group_id="O5">
            <title>160 mg COR-1</title>
            <description>single intravenous administration</description>
          </group>
          <group group_id="O6">
            <title>240 mg COR-1</title>
            <description>single intravenous administration</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Reporting Adverse Events (AEs)</title>
          <description>To assess the safety and tolerability of COR-1.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>intravenous 0.9 % NaCl</description>
        </group>
        <group group_id="E2">
          <title>10 mg COR-1</title>
          <description>single intravenous administration</description>
        </group>
        <group group_id="E3">
          <title>40 mg COR-1</title>
          <description>single intravenous administration</description>
        </group>
        <group group_id="E4">
          <title>80 mg COR-1</title>
          <description>single intravenous administration</description>
        </group>
        <group group_id="E5">
          <title>160 mg COR-1</title>
          <description>single intravenous administration</description>
        </group>
        <group group_id="E6">
          <title>240 mg COR-1</title>
          <description>single intravenous administration</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>not drug-related traumatic injury (achilles tendon) during sledging 8600 half-lives post drug admin.</sub_title>
                <description>Injury by sheet metal used for tobogganing 18 days after drug administration. Hospitalisation for 3 days (2 nights). Plastic reconstruction of the Achilles tendon, antibiotic treatment and wound dressing. Ambulatory follow up 31 days later.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>feeling of cold at infusion site when drug was added to cold saline solution</sub_title>
                <description>Caused by cold temperature of infusion solution. The event never reoccurred when solution was equilibrated to room temperature prior to injection.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI can discuss and publish trial results upon review of results communication by the sponsor. The sponsor can require changes to the communication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gary Peters, MD, Managing Director</name_or_title>
      <organization>Corimmun, GmbH</organization>
      <phone>001-215 628-5257</phone>
      <email>gpeters7@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

